Trump administration authorises 172 million barrel SPR drawdown as 32 IEA nations coordinate record emergency oil release
Read More 6 minute read Pharma Industry News CVKD expands clinical pipeline with acquisition of VLX-1005, a Phase 2 12-LOX inhibitor for HIT patients Discover how Cadrenal Therapeutics’ acquisition of VLX-1005 could reshape treatment options for heparin-induced thrombocytopenia and strengthen its anticoagulation pipeline. bySoujanya RaviDecember 13, 2025